Selective suppression of NF-κBp65 in hepatitis virus-infected pregnant women manifesting severe liver damage and high mortality

Division of Molecular Oncology, Institute of Cytology and Preventive Oncology, Noida, India.
Molecular Medicine (Impact Factor: 4.82). 09/2007; 13(9-10):518-26. DOI: 10.2119/2007-00055.Prusty
Source: PubMed

ABSTRACT Fulminant hepatitis in Asian pregnant women is generally caused by hepatitis E virus infection, and extremely high mortality is most common in them. Decreased cell-mediated immunity is considered a major cause of death in these cases, but what exactly influences decreased immunity and high mortality specifically during pregnancy is not known. We used electrophoretic mobility shift assays, immunoblotting, and immunohistochemical analysis to study the expression and DNA binding activity of NF-kB p50 and NF-kB p65 in pregnant fulminant hepatic failure (FHF) patients and compared them with their nonpregnant counterparts. In both PBMC and postmortem liver biopsy specimens the DNA-binding activity of NF-kB was very high in samples from pregnant FHF patients compared with those from nonpregnant women as well as pregnant women with acute viral hepatitis (AVH) without FHF. Further dissection of the NF-kB complex in supershift assays demonstrated complete absence of p65 in the NF-kB complex, which is formed by homodimerization of the p50 component in pregnant FHF patients. Western blotting and immunohistochemical analysis of the expression of p50 and p65 proteins both showed higher levels of p50 expression and a complete absence or a minimal expression of p65, indicating its nonparticipation in NF-kB-dependent transactivation in pregnant FHF patients. We suggest that the exclusion of p65 from the NF-kB transactivation complex seems to be a crucial step that may cause deregulated immunity and severe liver damage, leading to the death of the patient. Our findings provide a molecular basis, for developing novel therapeutic approaches.

Download full-text


Available from: Bhupesh Prusty, Aug 12, 2015
  • Source
    • "NFκB is activated in the livers of subjects with chronic hepatitis C, and expression of RelA in these livers is associated with lower degree of apoptosis, and slower progression to fibrosisassociated chirrosis (Boya et al., 2001). Likewise, RelA expression is suppressed in pregnant women with chronic hepatitis E (HEV) infection and correlates with the severe liver damage and high mortality seen in these patients (Prusty et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The liver plays a central role in the transformation and degradation of endogenous and exogenous chemicals, and in the removal of unwanted cells such as damaged, genetically mutated and virus-infected cells. Because of this function, the liver is susceptible to toxicity caused by the products generated during these natural occurrences. Hepatocyte death is the major feature of liver injury. In response to liver injury, specific intracellular processes are initiated to maintain liver integrity. Inflammatory cytokines including tumor necrosis factor (TNF)alpha and interleukin-6 (IL-6) are key mediators of these processes and activate different cellular response such as proliferation, survival and death. TNFalpha induces specific signaling pathways in hepatocytes that lead to activation of either pro-survival mediators or effectors of cell death. Whereas activation of transcription factor NF-kappaB promotes survival, c-Jun N-terminal kinases (JNKs) and caspases are strategic effectors of cell death in the TNFalpha-mediated signaling pathway. This review summarizes recent advances in the mechanisms of TNFalpha-induced hepatotoxicity and suggests that NF-kappaB plays a protective role against JNK-induced hepatocyte death. Identification of the mechanisms regulating interplay between the NF-kappaB and JNK pathways is required in the search for novel targets for the treatment of liver disease, including hepatitis and hepatocellular carcinoma.
    Biological Chemistry 08/2009; 390(10):965-76. DOI:10.1515/BC.2009.111 · 2.69 Impact Factor
  • Source
    • "There were increased levels of estrogen, progesterone and βHCG in HEV-positive pregnant patients with fulminant hepatitis compared to HEV-negative patients and controls (Jilani et al 2007). Selective suppression of nuclear factor kappa B (NFκB) p65 in pregnant compared to non-pregnant fulminant hepatitis patients has also been proposed to cause liver degeneration, severe immunodefi ciency and multiorgan failure (Prusty et al 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The hepatitis E virus (HEV) is a small RNA virus and the etiological agent for hepatitis E, a form of acute viral hepatitis. The virus has a feco-oral transmission cycle and is transmitted through environmental contamination, mainly through drinking water. Recent studies on the isolation of HEV-like viruses from animal species also suggest zoonotic transfer of the virus. The absence of small animal models of infection and efficient cell culture systems has precluded virological studies on the replication cycle and pathogenesis of HEV. A vaccine against HEV has undergone successful clinical testing and diagnostic tests are available. This review describes HEV epidemiology, clinical presentation, pathogenesis, molecular virology and the host response to HEV infection. The focus is on published literature in the past decade.
    Journal of Biosciences 12/2008; 33(4):451-64. DOI:10.1007/s12038-008-0064-1 · 1.94 Impact Factor
  • Source
    • "The protective role of NF-kB in adult liver was confirmed in the ConA hepatitis model (Maeda et al., 2003), and shown to involve inhibition of both apoptosis and necrosis (Kamata et al., 2005). Some clinical cases support the antiapoptotic activity associated with NF-kB inhibitor because of diminished activation by expression of RelA/ p65 caused by hepatitis virus infection (Prusty et al., 2007). As mentioned above, NF-kB exerts its pro-survival effects through several mechanisms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The NF-kappaB signaling pathway has particular relevance to several liver diseases including hepatitis (liver infection by Helicobacter, viral hepatitis induced by HBV and HCV), liver fibrosis and cirrhosis and hepatocellular carcinoma. Furthermore, the NF-kappaB signaling pathway is a potential target for development of hepatoprotective agents. Several types of drugs including: selective estrogen receptor modulators (SERMs), antioxidants, proteasome inhibitors, IKK inhibitors and nucleic acid-based decoys have been shown to interfere with NF-kappaB activity at different levels and may be useful for the treatment of liver diseases. However, NF-kappaB also plays an important hepatoprotective function that needs to be taken into consideration during development of new therapeutic regimens.
    Oncogene 11/2008; 27(48):6228-44. DOI:10.1038/onc.2008.300 · 8.56 Impact Factor
Show more